Ö÷²¥ÓÕ»ó

Object moved to here.

Ö÷²¥ÓÕ»ó :: Pilot & Feasibility Program Application

Ö÷²¥ÓÕ»ó


MR Elastography for Noninvasive Assessment of Fibrosis in Diabetic Kidney Disease
Summary Data Summary
Applicant Brown, Robert
E-Mail Address rbrown@bidmc.harvard.edu
Project Title MR Elastography for Noninvasive Assessment of Fibrosis in Diabetic Kidney
Disease
CBU ID 14GHSU1361
External SubContract ID 25732-65
Diabetic Complication Nephropathy
Funding Program Group Pilot & Feasibility [PF2014]
Abstract There has been an increasing incidence of chronic kidney disease (CKD),
particularly secondary to diabetes mellitus, in the USA leading to a large
burden of cardiovascular mortality and renal failure. Kidney scarring, known as
fibrosis, is considered the final common pathway of kidney injury leading to
progressive impairment of renal function in diabetic nephropathy (DN).
Therefore, it is important to know the degree of kidney fibrosis in order to
determine treatment and prognosis, but there is currently no simple, reliable,
and non-invasive way to do so. Kidney biopsy, the invasive gold standard, has
sampling error and its risk precludes frequent repetition. A novel technique
using magnetic resonance imaging known as MR elastography (MRE) has been
developed to assess tissue elasticity. Our preliminary data suggests that tissue
shear stiffness as measured using MRE may correlate with pathologic kidney
fibrosis and/or kidney function in our pilot group of normal subjects and CKD
patients. A finding that MRE could non-invasively estimate the degree of kidney
fibrosis or scarring would greatly improve our care of patients with DN. It
would provide a quantum leap in our ability to assess tissue damage, follow
disease progression, and evaluate response to treatments designed to prevent
fibrosis and slow tissue damage in patients with diabetic kidney disease.

We are proposing to test whether non-invasively measured MRE elasticity,
together with MR arterial spin labeling and phase contrast measurement of kidney
perfusion, correlates with fibrosis as graded by kidney biopsy and with standard
kidney function tests (creatinine based estimated glomerular filtration rate) in
patients with Type 1 and Type 2 diabetes in early and late stages of DN.
Furthermore, we will assess whether MRE measured shear stiffness is abnormal and
can detect early kidney fibrosis in diabetic patients with hyperfiltration
and/or microalbuminuria with preclinical DN prior to reductions in eGFR. This
technique may allow differentiation of structural fibrotic changes from
reversible functional changes in patients with hemodynamic effects that
complicate evaluation of DN.
Application PDF Application Research Plan
Status Contract Executed
Key Personnel
Salary Total Costs 53566
Supply Total Costs 0
Equipment Total Costs 0
Travel/Other Total Costs 36216
Direct Costs 89782
Indirect Costs Proposed 10135
Total Costs Proposed 99917
Total Costs Approved 99917
Start Date 10/1/2014
End Date 9/30/2015
IFO Name LeRoy, Russel
IFO E-Mail Address resadmin@bidmc.harvard.edu
IACUC/IRB No. 999999
IACUC/IRB Institution Beth Israel Deaconess Medical
Entity ID No. 1042103881A1
Report Request Date 10/30/2015
T1D NO
TypeCount
Invoices 19
Progress Reports 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical9/30/2015$15,110.47-$15,110.47$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical9/1/2019$52.92$3.85$56.77$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical8/31/2015$12,204.95-$12,204.95$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical7/31/2015$8,989.75-$8,989.75$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical6/30/2016$4,671.58$466.82$5,138.40$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical6/30/2015$3,551.63-$3,551.63$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical5/31/2016$4,916.84$490.06$5,406.90$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical5/31/2015$2,750.27-$2,750.27$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical4/30/2016$2,203.24$219.99$2,423.23$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical4/30/2015$2,715.35-$2,715.35$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical3/31/2016$2,352.23$235.23$2,587.46$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical3/31/2015$15,885.53-$15,885.53$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical2/29/2016$4,715.63$471.23$5,186.86$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical2/28/2015$3,730.77-$3,730.77$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical12/31/2015$2,391.67$235.23$2,626.90$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical11/30/2015$3,902.22-$3,902.22$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical10/31/2016$1,324.95$121.75$1,446.70$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical10/31/2015$2,695.18-$2,695.18$271.20View PDF
  View  14GHSU136125732-65Beth Israel Deaconess Medical1/31/2016$2,942.23$294.23$3,236.46$271.20View PDF


Reports
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)